


AMY-101 TFA

Chemical Properties

CAS No. :	1789738-04-0
Formula:	C ₈₅ H ₁₁₈ F ₃ N ₂₃ O ₂₀ S ₂
Molecular Weight:	1903.11
Storage:	Keep away from moisture Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	AMY-101 TFA is a cyclic peptide that acts as an inhibitor of complement C3 and an immunomodulator, used for the treatment of gingivitis and periodontitis. It significantly reduces inflammation and lowers levels of MMP-8 and MMP-9. AMY-101 TFA also has a mitigating effect on lung inflammation/damage in patients with COVID-19-induced ARDS and acute kidney injury associated with SARS-CoV-2.
Targets(IC50)	MMP, Complement System, SARS-CoV
In vivo	Methods Mice were treated with AMY-101 TFA (4 mg/kg, subcutaneously, every 24 hours for 28 days) to test whether AMY-101 TFA is effective when administered systemically. Results: AMY-101 TFA resulted in a significant and sustained reduction in PPD, a measure of tissue damage. [1]
Animal Research	Animal Model: Fifteen adult male cynomolgus monkeys (7-15 years old; 5.0-7.6 kg). Dosage: 0.1 mg/site; 50 µL of 2 mg/mL solution. Administration: Injected locally (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment) [1].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.5255 mL	2.6273 mL	5.2546 mL
5 mM	0.1051 mL	0.5255 mL	1.0509 mL
10 mM	0.0525 mL	0.2627 mL	0.5255 mL
50 mM	0.0105 mL	0.0525 mL	0.1051 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kajikawa T, et al. Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. *Mol Ther Methods Clin Dev.* 2017 Aug 18;6:207-215.

Mastaglio S, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. *Clin Immunol.* 2020 Apr 29:108450.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481